21st Century Cures Act: A Boon For Drug Companies, Research Programs

Published December 7, 2016 at 12:33 PM EST

House Majority Leader Kevin McCarthy of Calif., left, shakes hands with Rep. Tim Murphy, R-Pa., center, and Rep. Fred Upton, R-Mich., right, during a news conference on Capitol Hill in Washington, Wednesday, Nov. 30, 2016. (Susan Walsh/AP)

The Senate is expected to vote this afternoon on the 21st Century Cures Act. It is considered landmark legislation that would provide funding for research programs like Vice President Joe Biden’s moonshot against cancer.

It will also make significant changes in how drugs are tested and approved.

The act passed in the House overwhelmingly and is expected to easily pass the Senate as well.

NPR’s Richard Harris (@rrichardh) joins Here & Now‘s Jeremy Hobson to discuss what this legislation will mean for drug companies, medical research and more.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Donate